Special Issue "Vaccines and Therapeutics against Emerging Viruses"
A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Viral Immunology, Vaccines, and Antivirals".
Deadline for manuscript submissions: 1 October 2021.
Special Issue Editors
Interests: mechanistic studies of viral entry and replication and antiviral drug development, particularly on small molecule drugs; mechanistic studies of emerging viruses such as infleunza virus, filoviruses, Henipah virus and SARS-CoV-2
Special Issues and Collections in MDPI journals
Interests: emerging viruses; virus–host cell interactions; enveloped virus entry, viral glycoprotein structure and function and virus receptors; viral vaccines and countermeasure development; paramyxoviruses; henipaviruses; Nipah and Hendra; filoviruses Ebola and Marburg; australian bat lyssavirus; animal models
Interests: antivirals; viral entry inhibitor; fusion inhibitor; antiviral vaccine
Special Issues and Collections in MDPI journals
Special Issue Information
Dear Colleagues,
Emerging and re-emerging viruses are serious public concerns—especially at present, as we currently face one of the deadliest pandemics in human history: COVID-19, which is caused by SARS-CoV-2. This is a reminder that other emerging and re-emerging viruses, such as Ebola virus, Zika virus, Lassa fever virus, influenza A virus, Nipah virus, also have pandemic potential. Therefore, there is an urgent need to develop novel vaccines and therapies since only limited options are available against these viruses. In particular, the broad-spectrum antivirals and vaccines against constantly mutating viruses are urgently needed. Driven by our understanding of the mechanisms of viral pathogenesis, novel techniques have been developed and used to engineer a new generation of vaccines and therapeutics against emerging viruses, including cell biology studies, live-cell imaging, structural biology, systems biology, etc.
In this Special Issue, we welcome submissions of research or review articles on recent advances in our understanding of vaccines and therapeutics against emerging viruses. Topics may include, but are not limited to, structural and functional study of vaccines, antigens, adjuvants, antibodies, peptides, small molecules, herbal ingredients, and any innovative therapeutic or preventive strategies against emerging viruses.
Prof. Dr. Lijun Rong
Prof. Dr. Christopher C. Broder
Prof. Dr. Lu Lu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Emerging viruses
- Vaccines
- Antivirals
- Broad-spectrum
- Viral inhibitor
- Antibody
- Small molecules
- Peptides
- Adjuvants